Radiation, immunotherapy, and targeted therapy before surgery for liver cancer with portal vein tumor thrombus
Part of Cancer, Digestive system clinical trials.
This trial tests whether combining radiation (IMRT) with two drugs—camrelizumab (an immunotherapy) and apatinib (a targeted therapy)—before surgery can help people with liver cancer that has spread to the main blood vessel of the liver (portal vein). The goal is to shrink the tumor and improve surgical outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have liver cancer that can be removed with surgery, and it has spread to the main blood vessel in your liver (portal vein tumor thrombus).
- You are between 18 and 75 years old.
- Your liver function is good (Child-Pugh class A) and you are able to perform daily activities without much help (ECOG score 0 or 1).
- You have not had any prior cancer treatment like surgery, chemotherapy, radiation, or targeted therapy.
- You are willing to provide a fresh tumor sample and blood samples for research.
- You have adequate blood cell counts and organ function as determined by lab tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of focused radiation (SBRT), an immunotherapy drug (adelimumab), and a targeted therapy pill (apatinib) before surgery for liver cancer. The goal is to shrink tumors enough to make surgery possible or more effective.
This trial tests a combination of treatments for liver cancer that has spread to the main portal vein. It uses a special stent, radiation seeds, and targeted therapies to shrink the tumor and improve blood flow. This may help patients who haven't had certain prior treatments.
This study is testing whether combining targeted therapy with immunotherapy can help people with advanced liver cancer that cannot be surgically removed. The goal is to see if this combination treatment is safe and effective.
This trial tests a combined treatment plan—chemo delivered to the liver, targeted therapy, anti-VEGF therapy, and immunotherapy—to control unresectable hepatocellular carcinoma (HCC). It may help shrink tumors or slow progression when surgery isn’t possible.
This trial tests whether adding targeted radiation therapy can help people with liver cancer that cannot be surgically removed. It is for people who have already received a combination of TACE, lenvatinib, and sintilimab and whose tumors have not grown.
This trial combines two immunotherapy drugs with a targeted therapy, radiation, and a liver-directed chemotherapy infusion for liver cancer that has spread to the portal vein (the main blood vessel to the liver). The goal is to see if this combination can shrink tumors and help people live longer.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.